US-based biopharmaceutical services provider Parexel International has launched a new unit committed to addressing the product development challenges of small and mid-sized biopharmaceutical companies.
The Parexel BioPharm Unit will offer customised solutions to accelerate patient recruitment, get studies up and running more quickly, reduce the time to database lock, and improve overall efficiency in meeting critical development milestones.
The unit, which includes a senior management leader and a dedicated team offering “ongoing, frequent communication and proactive solutions”, is aimed in particular at small pharmaceutical and biotechnology sponsors whose needs are “meaningfully different” from those of their larger counterparts, Parexel noted.
Recent data from Pharmaprojects indicate that small and mid-sized companies are “the engine of the biopharmaceutical industry”, with 81% of ongoing development programmes originating from sponsors outside the top 25 biopharmaceutical companies, it noted.
The Parexel BioPharm Unit endeavours to support this pipeline by providing “the precise expertise, global infrastructure, operational excellence and turn-key technologies needed to help small biopharmaceutical companies advance their drugs through the development cycle”, Parexel said.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.